Gimeracil
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Gimeracil
- Molecular weight
- 145.54
- Structure (SMILES)
- Oc1cc(O)c(Cl)cn1
- gimeracil component of teysuno
- Gimeracil component of teysuno
- gimeracil
- Gimeracil
- GIMERACIL [EMA EPAR]
- gimeracil [INN]
- GIMERACIL [JAN]
- GIMERACIL [MI]
- Gimeracil [WHO-DD]
- gimeracil and oteracil potassium capsule
- gimeracil ema epar
- gimeracil inn
- gimeracil jan
- gimeracil mi
- gimeracil who dd
- gimeracilo
- Gimeracilo
- gimestat
- Gimestat
- teysuno component gimeracil
- TEYSUNO COMPONENT GIMERACIL
- CAS registry numbers
- 103766-25-2
- ChEMBL ID
- CHEMBL1730601
- InChIKey
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N
- PubChem compound IDs
- 54679224
- FDA ingredient codes (UNII)
- UA8SE1325T
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -racil
Mechanisms of action
- Mechanism
- Dihydropyrimidine dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Dihydropyrimidine dehydrogenase [NADP(+)]
- Protein identifier
- Q12882
Open Targets mechanisms
- Mechanism
- Dihydropyrimidine dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Dihydropyrimidine dehydrogenase [NADP(+)]
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- DPYD
- Protein identifier
- Q12882
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002916
- Subject identifier
- D004938
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003860
- Subject identifier
- D010190
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003897
- Subject identifier
- D013274
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Carcinoma, Neuroendocrine
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002120
- Subject identifier
- D018278
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
And 10 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003897
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003060
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003219
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 3
And 24 more, listed on the interactive page.
- Event
- alanine aminotransferase increased
- Reports
- 5
- Reporting signal score
- 6.79588
- Event
- anaemia
- Reports
- 15
- Reporting signal score
- 23.3184
- Event
- anal erosion
- Reports
- 1
- Reporting signal score
- 6.12832
- Event
- arterial thrombosis
- Reports
- 2
- Reporting signal score
- 7.59051
- Event
- biliary tract disorder
- Reports
- 2
- Reporting signal score
- 8.8983
- Event
- bone marrow failure
- Reports
- 14
- Reporting signal score
- 47.5914
- Event
- cardiotoxicity
- Reports
- 4
- Reporting signal score
- 12.9125
- Event
- cholangitis acute
- Reports
- 2
- Reporting signal score
- 9.74658
- Event
- collateral circulation
- Reports
- 1
- Reporting signal score
- 6.12832
- Event
- decreased appetite
- Reports
- 16
- Reporting signal score
- 31.3596
- Event
- diarrhoea
- Reports
- 19
- Reporting signal score
- 19.3357
- Event
- disease progression
- Reports
- 5
- Reporting signal score
- 6.306
- Event
- fatigue
- Reports
- 13
- Reporting signal score
- 8.19683
- Event
- gastric cancer recurrent
- Reports
- 1
- Reporting signal score
- 6.44656
- Event
- gastric perforation
- Reports
- 2
- Reporting signal score
- 7.97808
- Event
- hepatic function abnormal
- Reports
- 7
- Reporting signal score
- 16.4285
- Event
- hepatitis acute
- Reports
- 2
- Reporting signal score
- 6.70845
- Event
- hepatitis b
- Reports
- 2
- Reporting signal score
- 7.08058
- Event
- hyperbilirubinaemia
- Reports
- 4
- Reporting signal score
- 11.7227
- Event
- hypoalbuminaemia
- Reports
- 3
- Reporting signal score
- 9.03375
- Event
- implant site dehiscence
- Reports
- 1
- Reporting signal score
- 6.44656
- Event
- itching scar
- Reports
- 1
- Reporting signal score
- 6.54494
- Event
- leukopenia
- Reports
- 9
- Reporting signal score
- 19.5268
- Event
- metastases to bladder
- Reports
- 2
- Reporting signal score
- 12.5086
- Event
- metastases to bone
- Reports
- 3
- Reporting signal score
- 7.81241
And 22 more, listed on the interactive page.
- NCT00072787
- NCT00088816
- NCT00134095
- NCT00142350
- NCT00150670
- NCT00152217
- NCT00182611
- NCT00195572
- NCT00202969
- NCT00209638
- NCT00209664
- NCT00209729
- NCT00216034
- NCT00278863
- NCT00287768
- NCT00400179
- NCT00503321
- NCT00687843
- NCT00816543
- NCT00915382
- NCT00960349
- NCT00985556
- NCT01283204
- NCT01285557
- NCT01286766
And 200 more, listed on the interactive page.
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 53.35
- Calculated partition coefficient (ALogP)
- 1.15
- Calculated partition coefficient (XLogP)
- -0.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 9
- Molecular formula
- C5H4ClNO2
- Monoisotopic mass
- 144.9930561
- Natural product
- Yes
- Recorded assays
- 809
- Active assays
- 28
- Confirmatory
- Screening
Related records
Trials (16)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
- CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
- Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
- DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
- Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
- Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
- Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
In development for (34)
- Adenocarcinoma Phase 3
- Biliary tract cancer Phase 3
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Cancer Phase 2
- Carcinoma of esophagus Phase 3
- Cervical cancer Phase 1
- Cholangiocarcinoma Phase 3
- Colorectal adenocarcinoma Phase 3
- Colorectal cancer Phase 3
- Colorectal neoplasm Phase 3
- Esophageal cancer Phase 3
- Esophageal squamous cell carcinoma Phase 3
- Exocrine pancreatic carcinoma Phase 3
- Gastric adenocarcinoma Phase 3
- Gastric cancer Phase 3
- Gastric carcinoma Phase 3
- Gastric neoplasm Phase 3
- Gastroesophageal junction adenocarcinoma Phase 3
- Head and neck cancer Phase 3
Targets (1)
- DPYD Dihydropyrimidine dehydrogenase inhibitor